🔗 Share this article

Given that the United States continues making unprecedented adjustments to its vaccination schedules, a particular individual appears in a surprising turn: Dr. Tracy Beth Høeg, an American of Danish descent physician and public health researcher who rose to prominence by expressing skepticism about coronavirus vaccinations in the global health crisis and has zeroed in on possible deaths after COVID-19 vaccination in her recent tenure at the Food and Drug Administration.

Proposed Overhauls to Childhood Vaccine Schedule

Health officials planned to reveal sweeping changes to the pediatric immunization program recently, bringing the US with Denmark’s national calendar, according to reports – a substantial departure that would put the US at odds with much of the global community with no evidence for public health gain. The announcement has been postponed until the coming year.

Instead of the top vaccines chief, Dr. Høeg is set to address the audience at the meeting. She was just designated interim head of the FDA’s drug evaluation center, the fifth person to lead the center this calendar year.

A Shift at the Regulatory Body

Høeg's temporary position could signify a tighter collaboration between the drug and vaccine centers as Høeg and Dr. Prasad strengthen their influence at the FDA – and it signals a greater focus upon reevaluating previously authorized immunizations at the FDA.

Høeg has frequently advocated for discontinuing some childhood vaccine recommendations in the US so as to align more similar to the Danish model, a country with nationalized medicine and a citizenry roughly the population of the state of Wisconsin.

To date comments, she has continued to focus on immunizations – typically the responsibility of Prasad, head of the FDA’s CBER – rather than medication approval.

Questions Over Background

The appointee has no obvious experience in medication creation, regulation or administrative roles, which has been customary for previous directors of the Center for Biologics Evaluation and Research. She has served at the FDA as a top consultant to the agency head and CBER since spring.

“She appears not to have any of the qualifications” for running the pharmaceutical oversight division, remarked a neurologist and psychiatrist. “She lacks experience running a scientific study. She is not versed in running a major agency. She lacks background in pharmaceutical oversight.”

Past heads of CBER would “be deeply familiar with laws and regulations and the science of drug development”, commented a former acting FDA commissioner. “Clearly, she lacks the type of experience that former directors who headed the center have had.”

CDER has an vast portfolio at the FDA, Woodcock pointed out.

“Everybody just focuses on the innovative therapies, but the off-patent medication office approves numerous generic medications. There’s a biosimilars program, non-prescription drug unit and so forth, and each of these have to be supervised,” she noted. “The responsibility you overlook, that is precisely what that I always told people is going to come back to haunt you.”

Additionally, a substantial administrative aspect to the position, which manages more than 5,000 staff members. “It’s a huge management job, if you do it right,” Woodcock concluded.

Official Statement and Contentious Initiatives

Regarding concerns about Dr. Høeg's qualifications and whether this assignment represents more teamwork among agency officials on immunizations, a spokesperson responded that the “questions are based on inaccurate presumptions”.

“This background is consistent with the duties of her role,” the representative said, citing the period Høeg spent counseling the agency head on “medication safety and regulatory science, including computational safety modeling and shot safety tracking”.

As acting director, Dr. Høeg assumes responsibility for the commissioner’s controversial priority voucher program, a contentious one-day medication authorization process that reportedly troubled her former heads. “How are these medications being picked for this expedited pathway? Who makes the choices?” Howard questioned. “There is a lot of secrecy happening at the regulatory body right now.”

Broadly speaking, he stated, “the FDA seems to be moving towards laxer oversight of all drugs, except for vaccines.”

Documented Track Record on Vaccines

With vaccines, Høeg has a more documented, if problematic, track record, critics said. She published a research paper using non-validated crowd-sourced reports to assess the rate of heart inflammation after COVID-19 immunization. She consulted for the state of Florida top health official Joseph Ladapo, who allegedly have altered data to indicate Covid vaccines are riskier than they are.

Among her “policy goals” for the new federal leadership included altering regulations for novel immunizations and discontinuing “non-essential” vaccines, she remarked after the election on a audio program. At the FDA, Høeg has according to sources suggested preventing teenage boys from obtaining COVID-19 vaccines.

“She is an thorough dogmatist who commences with her conclusions and reverse-engineers to fit the evidence in a very disingenuous, untruthful way,” Howard argued.

Consolidating Power and a “Revenge Tour”

Dr. Høeg aligned with fellow dissenters, {like|